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Increasing  evidence  indicates  that a dysregulated  immune  system,  as  the  one  found  in allergic  disor-
ders,  can  affect  survival  of  tumor  cells.  A  possible  association  between  allergies  and  risk  of  hematologic
malignancies  has been  examined  in  several  epidemiological  studies;  however,  results  were  not  always
consistent.vailable online 12 August 2014
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The aim  of this  review  is  to  report  the  preclinical  and  clinical  data,  which  support  a correlation  between
allergy  and  hematologic  neoplasms.
Immune  system  modulation  could  represent  a powerful  tool  in  the prevention  and  treatment  of  hema-
tologic  malignancies.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
 cell tolerance license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
Allergic diseases require sensitization of a predisposed individ-
al to a speciﬁc antigen. Exposure of a susceptible individual to an
llergen results in its processing by antigen presenting cells (APC),
ncluding macrophages and dendritic cells (DC) located throughout
he body surfaces in contact the outside environment, such as nose,
recognition through various ligand/receptor interactions and on
the cytokine micro-environment, with IL-4 directing a T helper
(Th)2 response and interferon (IFN) a Th1 proﬁle.
Peripheral T cell tolerance to environmental antigens is crucial
for a healthy immune response and no allergy. The balance between
Th2 cells and T regulatory (Treg) cells has a critical role in the gen-
eration of immune responses to environmental antigens. Allergicungs, eyes, skin, and intestine. These APCs process the allergen
rotein and present the epitope bearing peptides via their MHC  to
articular T cell subsets. T cell responses depend on both cognate
∗ Corresponding author. Tel.: +39 0902212364; fax: +39 0902213397.
E-mail address: aallegra@unime.it (A. Allegra).
1 These authors have equally contributed to the work
ttp://dx.doi.org/10.1016/j.leukres.2014.08.004
145-2126/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unindividuals display an aberrant activation and expansion of Th2
cells. It appears that aberrant activation of Th2 cells in allergy is
secondary to impaired mechanisms of peripheral T cell tolerance
that is normally mediated by antigen-speciﬁc T cell anergy, Treg
cells, and suppressive cytokines, IL-10 and TGF- [1].
However, increasing evidence indicates that dysregulation of
the immune system, as the one found in allergic dysregulation, can
affect survival of tumor cells. [2].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The aim of this review is to report the preclinical and clinical
ata, which support a correlation between allergy and hematologic
eoplasms.
. Allergy and hematologic malignancies
The majority of studies reported in literature have explored the
elationship between allergy and lymphoma or acute lymphoblas-
ic leukemia. In fact, it is only for these diseases that the strongest
orrelations with the allergic state have been detected, while for the
ther hematological diseases reports are sporadic and sometimes
necdotal.
A possible association between allergies and risk of hematologic
alignancies (HM) has been examined in several epidemiological
tudies; however, results were not always consistent [3].
In contrast, inverse associations were reported mainly in case-
ontrol design studies. There have been several investigations
egarding deﬁnition and measurement of allergies and the sub-
ypes of HM assessed, however, an inverse association with history
f allergies has been reported for HM as a group [4], lymphoma
verall [5,6], Hodgkin’s lymphoma (HL), Non Hodgkin lymphoma
NHL)[7–10], Acute Lymphoblastic Leukemia (ALL) [11,12], and
ultiple myeloma (MM)[13] (Table 1).
Shadman et al. used the Vitamins and Lifestyle (VITAL) cohort
o examine the association between allergies and risk of hemato-
ogic malignancies. From 2000 to 2002, 66,212 participants, aged
0–76, completed a baseline questionnaire on cancer risk factors,
edical conditions, allergies, and asthma. Through 2009, incident
Ms  (n5681) were identiﬁed via linkage to the Surveillance, Epi-
emiology, and End Results Cancer Registry.
After adjustment for factors possibly associated with HMs,
 history of airborne allergy was associated with increased
isk of HMs  (hazard ratio [HR] = 1.19 [95% conﬁdence interval:
.01–1.41], P = 0.039) in Cox proportional hazards models. This
ssociation was limited to allergies to plants/grass/trees (HR = 1.26
1.05–1.50], P = 0.011) and was strongest for some mature B-
elllymphomas (HR = 1.50 [1.14–2.00], P = 0.005). Gender-stratiﬁed
nalyses revealed that the associations between airborne aller-
ies overall and those to plants, grass, and trees were only
een in women (HR = 1.47 [1.14–1.91], P = 0.004; and HR = 1.73
1.32–2.25], P < 0.001) but not men  (HR = 1.03 [0.82–1.29], P = 0.782;
nd HR = 0.99 [0.77–1.27], P = 0.960) [14]. The study indicates a
oderately increased risk of HMs  in women but not in men  with a
istory of allergies to airborne allergens, especially to plants, grass,
r trees. However, this association was not uniform across all the
ubtypes of HM,  rather it was primarily found in some mature B-cell
eoplasms.
Several other studies have attempted to ascertain the risk of
cute and chronic lymphoid malignancies in patients suffering
rom allergic diseases. In a US veterans study, a history of “total
llergic conditions” as documented in the hospital records was
ssociated with a diagnosis of NHL (risk ratio [RR] = 1.4 [1.3–1.5]).
igniﬁcant associations were also observed with speciﬁc allergic
onditions such as alveolitis, dermatitis, and erythema, but not
sthma [15].
Other studies indicate a positive association, especially for
odgkin Lymphoma (HL) [16,17] or no effect [18].
Moreover, in a population-based study from the Swedish can-
er registries, an increased risk of lymphoplasmacytic lymphoma
as reported in patients who had a history of “any type of allergy
r chronic inﬂammatory conditions” based on previous hospital
ischarge information (RR = 1.2 [1.0–1.4]) [19].Different works have shown a correlation between speciﬁc aller-
ic diseases and hematological malignancies. In a Swedish cohort of
ore than 16,000 twins, the risk of leukemia was higher in patients
ith self-reported history of hives (RR = 2.1 [1.0–4.5]) while noarch 38 (2014) 1137–1144
association was  found between different subtypes of allergies and
incidence of leukemia, CLL, NHL or MM [20]
However, when evaluating risk of acute childhood leukemia in
allergic patients, Chang et al. [21] utilized a population-based case-
control design using medical claims data from the National Health
Insurance Research Database of Taiwan. Eight hundred forty-six
childhood ALL patients who  were newly diagnosed during 2000 to
2008 and were older than 1 but less than 10 years of age were indi-
vidually matched with 3374 controls based on sex, age, and time
at diagnosis (reference date for the controls). Conditional logistic
regression was  performed to assess the association between child-
hood ALL and allergies. An increased risk of ALL was observed in
those with allergy less than 1 year before ALL diagnosis (odds ratio
(OR) = 1.7, 95% CI: 1.5, 2.0), more than 1 year allergy before ALL diag-
nosis (OR = 1.3, 95% CI: 1.1, 1.5), and before 1 year of age (OR = 1.4,
95% CI: 1.1, 1.7).
In this study, childhood ALL was  positively associated with sub-
ject having allergies before 1 year of age less than 1 year before
diagnosis, and more than 1 year before diagnosis.
Association between childhood ALL and allergies is contrary to
the results of most previous studies. The inconsistency can partly
be explained by the sources of exposure data (medical records vs.
parental report), participation rate, and exposure latency.
Moreover, Nunez-Enriquez et al.  conducted a multi institutional
population-based case-control study on children with Down syn-
drome and found that asthma was  a risk factor for development
of acute leukemia (OR = 4.18 and 95% CI: 1.47–11.87) while, other
allergies had no effect or were protective [22].
The intrinsic immune dysregulation that was well described in
children with Down syndrome, likely had a signiﬁcant role in the
association between allergic phenomena and ALL [23].
However, Down syndrome might be a confounder in the relation
between asthma and acute leukemia. Altogether, Down syndrome
may be considered as the cause for both asthma and acute leukemia
thus drawing a causative link between asthma and acute leukemia
in this setting could be a raw conclusion [24].
Nonetheless, similar results were also reported by other authors.
In fact, several papers suggest that asthma is a risk factor for AL
in children with DS, whereas skin allergies seemed to protect the
population from AL. Children with DS are more vulnerable to the
effects of environmental factors that have been associated with the
development of AL [25,26].
Finally, children born to mothers with allergies are more likely
to have impairment of Tregs cells [27] and a decreased ability to
respond to microbial challenges [28]. Similarly, higher maternal
serum immunoglobulin E, an indicator of maternal allergy status,
was associated with a higher risk of childhood ALL [29].
However, while prospective cohort studies suggested an
increased risk of HM,  case-control studies failed to conﬁrm these
ﬁndings, rather they have shown an inverse relationship [30].
In fact, it has been proposed that allergies inﬂuence the develop-
ment of childhood leukemia. Different studies have been conducted
in this ﬁeld; however, their results are not conclusive, as several
works have concluded that allergies are risk factors or protective
factors [31–34].
Moreover, beyond this inverse association of allergic history
with childhood ALL, a similar association is highlighted when sero-
logic markers of allergic predisposition are used as an alternative
measure of allergy.
In a study conducted on 252 cases of childhood (0–14 years)
ALL, newly diagnosed allergen-speciﬁc IgEs, as markers of aller-
gic predisposition, against 24 of the most prevalent respiratory
and food allergens, were determined, using an enzyme immunoas-
say procedure for 199 children with ALL and 113 controls. Cases
were compared with controls through frequency distributions and
unconditional multiple logistic regression models to estimate ORs
C. Musolino et al. / Leukemia Research 38 (2014) 1137–1144 1139
Table  1
Summary of studies on allergy and risk of hematologic neoplasms.
First author/year Reference number Type of allergy Type of HM Statistics
Shadman M/2013 [14] Air born allergy (plants/grass/trees) HM mature B-cell lymphomas HR = 1.19 [95% CI: 1.01–1.41], P = 0.039
HR = 1.50 [1.14–2.00], P = 0.005
Koshiol J/2011 [15] Total allergic conditions NHL [RR] = 1.4 [1.3–1.5]
Kristinsson SY/2010 [19] Any allergy or chronic inﬂammatory
conditions
Lymphoplasmacytic lymphoma RR = 1.2 [1.0–1.4]
Soderberg KC/2004 [20] Hives Leukemia RR = 2.1 [1.0–4.5]
Chang  JS/2011 [21] Not speciﬁed ALL OR = 1.7, 95% CI: 1.5, 2.0, less than 1
year before the case’s ALL diagnosis
OR = 1.3, 95% CI: 1.1, 1.5, more than 1
year before the case’s diagnosis
OR = 1.4, 95% CI: 1.1, 1.7, before the age
of 1 year
Nunez-Enriquez JC/2013 [22] Asthma Acute leukemia OR = 4.18 and 95% CI: 1.47–11.87
Lariou MS 2013 [35] Self-reported-allergic history
Serum speciﬁc IgE
Food IgE
ALL OR = 0.49, 95% CI: 0.34-0.72
OR = 0.43, 95% CI: 0.22-0.84)
OR = 0.39, 95% CI: 0.18-0.83
Dikalioti SK/2012 [36] Not speciﬁed asthma NHL OR = 0.50, 95% CI: 0.27–0.92
OR = 0.43, 95% CI: 0.21–0.88
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M:  hematological malignances; NHL: non Hodgkin lymphoma; ALL: acute lympho
isk  ratio; OR: odds ratio.
nd 95% (CIs) regarding associations of allergy with childhood
LL.
Self-reported-allergic history (OR = 0.49, 95% CI: 0.34–0.72) and
ractically every one of its main components (respiratory, food, any
ther clinical allergy) were strongly and inversely associated with
LL. Likewise, the serum IgE inverse association was of the same
agnitude (OR = 0.43, 95% CI: 0.22–0.84) mainly due to food IgE
OR = 0.39, 95% CI: 0.18–0.83) [35].
There is a similar discrepancy between works reported in litera-
ure on lymphoma. Furthermore, the papers appear to highlight the
irect correlation between allergy and chronic lymphoprolifera-
ive dysregulations while other papers seem to light the protective
ffect.
Between 1996 and 2008, 277 children (aged 0–14 years) with
L (N = 111) or NHL (N = 166) were enrolled in Nationwide Registry
or Childhood Hematological Malignancies (NARECHEM), from a
reek hospital-based registry of childhood hematological malig-
ancies. Hospital controls were individually matched to cases on
ge and sex. Multivariate conditional logistic regression was used
o estimate ORs with 95% CIs for associations of allergic diseases and
ther covariates with childhood HL or NHL risk. Subsequently, the
uthors combined their results with those of a French case-control
tudy in a meta-analysis counting a total of 330 NHL cases/1478
ontrols and 239 HL cases/959 controls. After investigating on
ociodemographic, perinatal and environmental factors, childhood
HL was less prevalent among children with allergy associated
ymptoms (OR = 0.50, 95% CI: 0.27–0.92) or a history of asthma
OR = 0.43, 95% CI: 0.21–0.88). By contrast, allergy did not seem to be
ssociated with childhood HL risk, although statistical power was
imited. However, fewer seaside holidays and higher birth weight
ere also associated with increased childhood NHL risk. The com-
ined OR of the two studies for the association of asthma with
HL risk was: 0.52, 95% CI: 0.32–0.84, whereas for HL: 0.86, 95%
I: 0.51–1.45. Thus, allergy seemed to be strongly and inversely
ssociated with childhood NHL [36].
A powerful pooled analysis of adulthood NHL also showed an
pparent protective effect of asthma, hay fever and allergy against
-cell NHL [37].
Finally, a reduced MM risk was found among women  who  had a
edical history of allergy (OR = 0.4; 95% CI: 0.3–0.7). However, thistudy shows conﬂicting results because certain conditions (such
s allergy, bronchitis, psoriasis, and eczema) were associated with
educed risk of MM,  whereas others (such as asthma and hay fever)
ere not associated with multiple myeloma risk [38].MM OR = 0.4; 95% CI: 0.3–0.7
c leukemia; MM:  multiple myeloma; HR: hazard ratio; CI: conﬁdence interval; RR:
3. Allergy as risk factor: possible mechanisms
Various explanations have been proposed to account for the
observed increased incidence of HM in patients with immune dys-
regulation. Relevant factors could be genetic and environmental
risk factors, chronic activation and replication of lymphocytes and
the subsequent increased chance of mutations, and ﬁnally epige-
netic changes, for example, via effects on antigen recognition by T
cells [39].
Effects of the treatments used by patients with allergies on
the cancer risk do not seem to explain the association, as asso-
ciations between uses of antihistamines, leukotriene agonists, or
other common therapeutic agents for allergies with HM have not
been reported.
The association between allergy and childhood ALL suggests that
the two  diseases may  have a common biologic mechanism.
Two  paradigms, “missing immune deviation” and “reduced
immune suppression,” have been proposed to explain the biologic
basis of this hypothesis [40]. Moreover, in order to explain the
role of allergies as a risk factor for cancer, it is worth considering
the antigenic stimulation hypothesis which proposes that chronic
stimulation of the immune system will provoke randomly occur-
ring pro-oncogenic mutations in actively dividing cells [20].
For instance, chronic lymphocytic leukemia (CLL) is a tumor
of circulating B cells, variably stimulated and anergized following
exposure to antigen in lymphoid tissues [41].
The hyper reactivity of the B-cell receptor (BCR) to unknown
antigen ligation plays a pivotal role in CLL cell survival. Several
authors aimed to investigate the BCR signaling pathway using
proteomics to identify novel proteins which may have clinical rel-
evance in this disease [42].
Almost 30% of CLL patients share BCRs with restricted, quasi-
identical “stereotyped” immunoglobulin (IG) sequences with
highly homologous IG variable heavy-chain complementarity-
determining region 3 (VH CDR3), the key determinant of antigen
speciﬁcity. This ﬁnding, along with other structurally unique fea-
tures of CLL BCRs, strongly suggest that antigens, superantigens or
both may  play an active role in the disease [43]. The latter strongly
supports a role for persistent antigen stimulation in the clonal evo-
lution of CLL [44].A different lymphoprolipherative disease with the same patho-
genesis could be the Large Granular Lymphocyte (LGL) leukemia.
LGL leukemia represents a rare chronic lymphoproliferative
dysregulation of CTLs, a malignancy that involves lymphocyte
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nﬁltration of multiple organs, including the BM, liver, and spleen.
henotypically, LGL leukemia can arise from either CD3+ CTLs or
D3− NK cells. The World Health Organization (WHO) classiﬁ-
ation includes T-cell LGL leukemia in the subgroup of mature
eripheral T-cell neoplasms and distinguishes it from aggressive
K-cell leukemia [45].
LGL leukemia is thought to arise from chronic antigenic stim-
lation, with the long-term survival of LGL being promoted by
onstitutive activation of multiple survival signaling pathways [46].
During infection exposure or Ag stimulation, LGLs undergo vig-
rous proliferation by approximately 50,000-fold upon priming by
arget cells, and at a later time after Ag clearance, are selectively
liminated by a process called activation induced cell death (AICD).
owever, in LGL leukemia patients, the AICD process is dysfunc-
ional and activated CTL cells do not undergo apoptosis efﬁciently,
eading to an elevated number of LGLs in the peripheral blood. Mul-
iple cell survival pathways, including JAK2/STAT3, sphingolipid
ignaling, RAS/MEK/ERK, and SFK/PI3K/Akt, have been found to be
onstitutively activated in LGL leukemia patients. A system biology
pproach identiﬁed IL-15 and PDGF as master survival signaling
witches that may  have a deep effect on all known deregulations
n T-LGL leukemia [47–55].
An interesting datum could be that the treatment of leukemic
GL is based on immunosuppressive therapy, primarily using low
oses of methotrexate or cyclophosphamide.
Associations between multiple myeloma and past history of
isorders characterized by chronic immune dysfunction and/or
ntigen stimulation have also been suggested in epidemiological
tudies; however, there are inconsistencies in the literature on this
opic [56–59].
Antigenic targets of monoclonal gammopathy of undetermined
igniﬁcance (MGUS) and multiple myeloma (MM)  paraproteins
ave been suggested to play an important role as growth stim-
lators in the pathogenesis of these neoplasms. To identify such
argets, Preuss et al. screened cDNA libraries from human testis,
ung and breast cancer, bovine and porcine muscle and wheat
erm for reactivity with paraproteins in the sera from 115
atients with MGUS and MM.  Of >6 × 10(8) paraprotein–antigen
nteractions screened, an IgA paraprotein from a female patient
ound to sperm-speciﬁc cylicin-2, and 3 IgG paraproteins bound
o tripeptidyl-peptidase-II (TPP-2), insulin-like growth-factor
inding-protein-2 (IGFBP-2) and porcine kinesin. Speciﬁcity was
onﬁrmed by reverse Western blots using recombinant antigens.
he broad spectrum of auto-, allo- and heteroantigens as targets of
uman paraproteins in patients without signs of chronic antigenic
timulation renders a causal role of the antigenic stimulus in the
athogenesis of MGUS and MM as unlikely [60].
The importance of clinical or subclinical immune dysregulation
n development of HM in cases occurring in the general population,
ho comprise the majority of cases, is unclear. However, in allergic
ndividuals, antigenic stimulation subjects the immune system to
 chronically hyper reactive state, leading to an inﬂammatory cas-
ade of cellular and cytokine reactions that tax the host immune
esponse, provoke tissue injury, and eventually result in lymphoid
eoplasia [61].
Thus, a B-cell stimulatory host environment increases the risk
f B-cell NHL among immuno-competent persons, and a modiﬁed
attern of cytokines production could be relevant in the onset of
M.
IL-12 is important for normal immune development that shifts
he immune proﬁle from T-helper 2 dominant among newborns to
-helper 1 dominant with increasing age [62]. The absence of this
hift and the presence of a T-helper 2-dominant immune proﬁle are
ssociated with an increased risk of allergy, but IL-12 also appears
mportant for childhood ALL. In fact, a previous study reported
hat the variant G allele of the single nucleotide polymorphismarch 38 (2014) 1137–1144
rs583911 of the interleukin 12A gene, which codes for a part of
IL-12 cytokine, is associated with an increased risk of childhood
ALL [63].
Moreover, although IL-10 can be produced by many cell types, it
is produced by a type of T-regulatory cell known as T-regulatory 1
at particularly high levels to suppress overactive immune reaction
[64], and a recent study showed that children with ALL had lower
IL-10 level at birth than did healthy children [65], while cord blood
samples of children with allergy have exhibited a lower immune
response of the T regulatory 1-related cytokine IL-10 compared
with healthy children [66,67].
Finally, increased serum/plasma levels of molecules involved in
B-cell activation, including soluble sCD23, sCD27, sCD30, sCD44,
and CXCL13, have been associated with subsequent development of
AIDS-related NHL. B-cell activation is characterized by lymphocyte
proliferation, class switch recombination, and somatic hypermuta-
tion, all of which are prone to resultant errors in DNA that may  lead
to lymphomagenesis [68–71].
A different hypothesis could explain the correlation between
allergy and HM.
Although the deﬁnite causes of childhood leukemia are still
largely unknown, it is believed that a lack of “priming” by infections
during early childhood may  cause a dysregulated immune response
to infections later in childhood, leading to the development of
childhood leukemia, particularly acute lymphoblastic leukemia
(ALL) (Greaves’ “delayed infection” hypothesis) [72]. Moreover the
underlying biologic mechanism in the delayed infection hypothesis
is also applicable to the hygiene hypothesis proposed by Strachan to
explain the rising prevalence of allergy in the Western population
[73].
Given the similarities between the delayed infection hypothesis
of childhood leukemia and the hygiene hypothesis of allergy, it is
counterintuitive that in the majority of studies, an inverse associ-
ation between allergy and childhood leukemia (mostly childhood
ALL) [12,31,33,34,74–78] was observed with only one exception
[32].
An overactive and dysregulated immune reaction in response to
pathogens may  lead to the expansion of a preleukemic clone, result-
ing in the occurrence of additional mutations and the development
of childhood leukemia [72].
4. Allergy as protective factor: possible mechanisms
In comparison, allergies as protective factors can be explained in
terms of the immune-surveillance hypothesis, which suggest that
allergic diseases enhance the immune system’s ability to detect and
eliminate neoplastic cells.
The immune system has the ability to recognize and eliminate
nascent transformed cells in the body, thus preventing a majority
of potential cancers from developing. The presence of an allergic
condition could be a surrogate marker of increased vigilance of the
immune system in scrutinizing, identifying, and destroying cancer
cells [11].
In allergic subjects, there is bone marrow involvement with
reprogramming of bone marrow stem cells, regarded as ‘reﬂex”
nature of allergic disease. Allergic phenotype in an atopic child
may  lead to epigenetic reprogramming that in turn affects immune
surveillance by increasing antigen-presenting cell activity [79].
Hence, it seems that increased surveillance by hyperactive immune
system of allergic patients is a reality.
Another is the adrenal hypothesis, which proposes that infec-
tions produce changes in the hypothalamus-pituitary-adrenal axis
and subsequently an elevation in plasmatic cortisol, provoking the
elimination of leukemic and preleukemic cells. This mechanism
is possible under allergic conditions because the drugs commonly
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sed to treat allergies include corticosteroids, which could provide
he same protective effect against the development of AL that early
nfections provide [80].
A less plausible explanation could point to the antitumor activity
f histamine [81], a chemical mediator of allergic reactions that pro-
ects natural killer cells and T cells against oxygen radical-induced
amage and death by suppressing oxygen radical formation, and
lso optimizes lymphocyte activation by cytokines [82]. Clinical
rials in malignancies such as metastatic malignant melanoma and
cute myeloid leukemia have demonstrated that histamine dihy-
rochloride in combination with immunotherapy has the potential
o improve treatment outcome, further supporting the posssible
ntitumor effect of histamine [83,84].
On the other side, it has already been demonstrated that his-
amine may  play a role in mycosis fungoides, particularly in
dvanced stages of the disease. Histamines, but also other medi-
tors released by mast cells, are not only associated with pruritus,
ut may  have tumor growth promotion and immune-regulating
roperties [85,86].
The antihistamines clemastine and desloratadine can possess
mmune suppressive or regulatory properties including inhibi-
ion of antigen-speciﬁc as well as mitogen-induced lymphocytes
roliferation. These properties were independent on histamine-
-receptor expression, but dependent on extracellular signal
egulated kinase (ERK)-dependent proinﬂammatory cytokines
uch as TNF-a and IL-6 [87,88].
Döbbeling et al.  evaluated the effect of clinically approved anti-
istamines on the growth of CTCL cell lines. CTCL cell lines as well
s blood lymphocytes from patients with Sézary syndrome were
ultured with antihistamines, and the cells were analyzed for prolif-
ration, apoptosis, and expression of programmed death molecules
nd transcription factors. The two antihistamines clemastine and
esloratadine, induced potent reduction of the activities of the
onstitutively active transcription factors c-Myc, STAT3, STAT5a
nd STAT5b in mycosis fungoides and Sézary syndrome cell lines.
his inhibition was followed by apoptosis and cell death, espe-
ially in the Sézary syndrome-derived cell line Hut78 that also
howed increased expression of the programmed death-1 (PD-1)
fter clemastine treatment. In lymphocytes isolated from Sézary
yndrome patients, the CD4-positive fraction underwent apoptosis
fter clemastine treatment, while CD4-negative lymphocytes were
ardly affected [89].
There are more things in heaven and hearth . . .
. Allergy, sex and solid neoplastic diseases
Recent studies have demonstrated that serum eosinophil count
s inversely associated with colorectal cancer development, and a
istory of allergy decreases the risk of pancreatic cancer [90,91],
hile atopic exposures may  be protective against childhood rhab-
omyosarcoma (RMS). In a case-control study of 322 childhood
MS  cases and 322 pair-matched controls Lupo et al.  assessed
he following atopic conditions were assessed: allergies, asthma,
czema, and hives. As the two most common histologic types of
MS are embryonal (n = 215) and alveolar (n = 66), they evaluated
ffect heterogeneity of these exposures. Allergies (OR = 0.60, 95% CI:
.41–0.87), and hives (OR = 0.61, 95% CI: 0.38–0.97) were inversely
ssociated with childhood RMS. These exposures did not display
igniﬁcant effect heterogeneity between histologic types. This is
he ﬁrst study indicating that atopic exposures may  be protective
gainst childhood RMS, suggesting additional studies are needed
o evaluate the immune system’s role in the development of this
umor [92]
Thus, the relationship between allergy and solid neoplastic dis-
ases also appears to be an important ﬁeld of investigation.arch 38 (2014) 1137–1144 1141
However, a different and interesting ﬁeld of research is the dif-
ferent inﬂuence of sex on the risk of HM in allergic patients. In fact,
gender differences are reported in the association between history
of allergies and cancer. It is tempting to speculate that the addi-
tional effect of allergy may  reach statistical signiﬁcance in women
because of their lower baseline risk for the development of HM
compared to men. However, hormonal effects on the (dysregu-
lated) immune system and interactions with carcinogenesis may
offer an alternative biological explanation that will required further
mechanistic studies.
6. Conclusions and future perspectives
In the future, many other factors should be studied to investigate
the relationship between allergies and cancer, such as the inﬂu-
ence of tumors on the possible manifestation of allergy symptoms.
We have to consider that individuals with pre-clinical NHL expe-
rience immune suppression that leads to the reduction of allergic
symptoms [8].
However, after we have reviewed the most recent literature
on the relationship between allergy and cancer, we must try to
justify the discrepancies that exist and the different conclusions
reached by various authors. It is probable that different immuno-
logical alterations that accompany different allergies, may  affect
tumor susceptibility in a completely different way.
In both allergy and cancer biology, for example, antibodies may
be beneﬁcial or detrimental, depending on their epitope speciﬁcity
[93,94]. In allergy, speciﬁc immunotherapy (SIT) with allergens
aims to induce antibodies which block, but do not enhance the
allergic reaction. Similarly, in immunological targeting of antigens
overexpressed by malignant cells, growth-inhibitory antibodies are
preferred, whereas growth-stimulating speciﬁcities should be pre-
vented. Therefore, in both cases it is important to direct immune
responses to inhibitory antibody epitopes of the allergen/antigen
[95].
The importance of antibodies in activating immune responses
against tumors is now better appreciated with the emergence of
checkpoint blockade antibodies and with engineered antibody Fc
domains featuring enhanced capacity to focus potent effector cells
against cancer cells. Antibodies designed with Fc regions of the IgE
class can confer natural, potent, long-lived immune surveillance in
tissues through tenacious engagement of high-afﬁnity cognate Fc
receptors on distinct, often tumor-resident immune effector cells,
and through ability to activate these cells under tumor-induced
Th2-biased conditions. IgE is a novel anti-cancer modality, and sev-
eral IgE-based active and passive immunotherapeutic approaches
have been tried in different in vitro and in vivo model systems,
collectively suggesting the potential of IgE immunotherapies in
oncology [96].
The assumption on an inverse association between allergy
and IgE levels and cancer derives from epidemiological data [97].
IgE antibodies directed against a tumor-associated antigen could
speciﬁcally trigger an immediate local effector cell response against
the tumor cells [98]
Engineered anti-tumor IgE antibodies have a high cytotoxic
capacity due to interaction with potent effector cells. However,
natural IgE has also been described in squamous cell carcinoma
of the head and neck [99] and in pancreatic cancer where its cyto-
toxic potential was  also demonstrated [100]. The mechanisms of
anti-tumor IgEs have already been studied in detail in several pre-
vious experiments, among them ADCC and antibody-dependent
cell-mediated phagocytosis (ADCP) seem to be most important
[101–103].
However, although several studies suggest an increased risk of
HM in patients with reported history of allergies, this association
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as not uniform across all the subtypes of HM and it has be denied
n several works.
In this regard it should be remembered that even though we
ave listed several studies on the association between allergies
nd hematological malignancies, a vast majority of these studies
re epidemiological studies. Although the contribution of epidemi-
logic methods in elucidating the determinants and etiological
actors in human disease has a long history, some practical limi-
ations of epidemiologic methods have to be highlighted.
There are two main limitations to epidemiological studies: the
rst is statistical and gives rise to random errors; the other con-
erns demography and gives rise to systematic errors. Groups of at
east several thousand people would need to be followed through-
ut their lives in order to identify a statistically signiﬁcant excess
f cancer between two populations. The second limitation results
rom the need to match the study and control groups for any con-
ounding factors that may  inﬂuence the incidence of cancer. Unless
he study and control groups are drawn from a single homogeneous
opulation, it is rarely possible to match the groups, or to make
llowances for the differences, with sufﬁcient accuracy to detect,
ith conﬁdence, a small increase in cancer mortality. Any inade-
uacy in the matching may  give rise to a bias that cannot be reduced
erely by expanding the size of the groups [104].
Despite these limitations, epidemiologic studies have been
emarkably productive in elucidating etiological factors.
In conclusion, several studies provide empirical evidence that
llergic disorders are associated with a direct or inverse risk of
eveloping hematologic malignancies.
In fact, a dysregulation of the immune system might have both
ositive and negative inﬂuence on the occurrence of cancer. The
resence of an allergic condition could be a surrogate marker of
ncreased vigilance of the immune system in scanning for, iden-
ifying and destroying cancer cells. On the other hand, in allergic
ndividuals, antigenic stimulation subjects the immune system to
 chronically hyper reactive state, leading to an inﬂammatory cas-
ade of cellular and cytokine reactions that provoke tissue injury
nd eventually result in neoplasia.
It is therefore certain that there is a clear speciﬁcity between
lteration of the immune system and the onset of hematologic
alignancies. The cell type concerned, myeloid or lymphoid, age,
ex, and comorbidities seem able to change the type of inﬂuence
xerted by the immune system. Therefore, generalizations about
he inﬂuence of the immune system on hematologic malignancies
ppear unnecessary and misleading.
Further studies should assess the real impact of allergies on any
peciﬁc hematological disease.
Epidemiological studies that include the evaluation of different
mmunological effectors will be needed for a conﬁrmation of this
ssociation and to explain the intimate mechanisms that under-
ie the increased susceptibility or the protective effect exerted by
llergy on neoplastic diseases.
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